Literature DB >> 29079200

Female Fabry disease patients and X-chromosome inactivation.

Patrycja Juchniewicz1, Anna Kloska1, Anna Tylki-Szymańska2, Joanna Jakóbkiewicz-Banecka1, Grzegorz Węgrzyn3, Marta Moskot4, Magdalena Gabig-Cimińska4, Ewa Piotrowska5.   

Abstract

Fabry disease is an X-linked inherited lysosomal storage disorder caused by mutations in the gene encoding α-galactosidase A (GLA). Once it was thought to affect only hemizygous males. Over the last fifteen years, research has shown that most females carrying mutated allele also develop symptoms, demonstrating a wide range of disease severity, from a virtually asymptomatic to more classical profile, with cardiac, renal, and cerebrovascular manifestations. This variable expression in females is thought to be influenced by the process of X-chromosome inactivation (XCI). The aim of this study was to assess severity of the clinical phenotype, to analyze XCI patterns, and to estimate their effect on disease manifestation in twelve female Fabry disease patients from five unrelated Polish families. Our analyses revealed that patients presented with the broad range of disease expression - from mild to severe, and their clinical involvement did not correlate with XCI profiles. Female carriers of the mutation in the GLA gene with the random XCI may present with the wide range of disease signs and symptoms. Thus, XCI is not a main factor in the phenotype variability of Fabry disease manifestation in heterozygous females.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  FOS-MSSI; Heterozygotes; MSSI; Severity score; XCI

Mesh:

Substances:

Year:  2017        PMID: 29079200     DOI: 10.1016/j.gene.2017.10.064

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  18 in total

1.  Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants.

Authors:  Silvia Lombardi; Mattia Ferrarese; Saverio Marchi; Paolo Pinton; Mirko Pinotti; Francesco Bernardi; Alessio Branchini
Journal:  RNA Biol       Date:  2019-10-15       Impact factor: 4.652

2.  The Changing Landscape of Fabry Disease.

Authors:  Einar Svarstad; Hans Peter Marti
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-04       Impact factor: 8.237

3.  Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.

Authors:  Patrícia Varela; Gerson Carvalho; Renan Paulo Martin; João Bosco Pesquero
Journal:  Metab Brain Dis       Date:  2020-11-06       Impact factor: 3.584

Review 4.  Dosage Compensation in Females with X-Linked Metabolic Disorders.

Authors:  Patrycja Juchniewicz; Ewa Piotrowska; Anna Kloska; Magdalena Podlacha; Jagoda Mantej; Grzegorz Węgrzyn; Stefan Tukaj; Joanna Jakóbkiewicz-Banecka
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 5.  Storage diseases with hypertrophic cardiomyopathy phenotype.

Authors:  Luis Ruiz-Guerrero; Roberto Barriales-Villa
Journal:  Glob Cardiol Sci Pract       Date:  2018-08-12

6.  Novel GLA Mutation Promotes Intron Inclusion Leading to Fabry Disease.

Authors:  Patrícia Varela; Myrtes Martins Caldas; João Bosco Pesquero
Journal:  Front Genet       Date:  2019-09-27       Impact factor: 4.599

7.  Natural course of Fabry disease with the p. Arg227Ter (p.R227*) mutation in Finland: Fast study.

Authors:  Päivi Pietilä-Effati; Jukka T Saarinen; Eliisa Löyttyniemi; Reijo Autio; Maria Saarenhovi; Maria K Haanpää; Ilkka Kantola
Journal:  Mol Genet Genomic Med       Date:  2019-08-14       Impact factor: 2.183

8.  Clinical Diversity in Patients with Anderson-fabry Disease with the R301Q Mutation.

Authors:  Saori Yamamoto; Tasuku Nagasawa; Koichiro Sugimura; Atsuhiro Kanno; Shunsuke Tatebe; Tatsuo Aoki; Haruka Sato; Katsuya Kozu; Ryo Konno; Kotaro Nochioka; Kimio Satoh; Hiroaki Shimokawa
Journal:  Intern Med       Date:  2018-10-17       Impact factor: 1.271

9.  The clinical profiles of female patients with Fabry disease in Latin America: A Fabry Registry analysis of natural history data from 169 patients based on enzyme replacement therapy status.

Authors:  Ana M Martins; Gustavo Cabrera; Fernando Molt; Fernando Suárez-Obando; Régulo A Valdés; Carmen Varas; Meng Yang; Juan M Politei
Journal:  JIMD Rep       Date:  2019-08-05

10.  Heterozygous Deletion of the SHOX Gene Enhancer in two Females With Clinical Heterogeneity Associating With Skewed XCI and Escaping XCI.

Authors:  Yixi Sun; Yuqin Luo; Yeqing Qian; Min Chen; Liya Wang; Hongge Li; Yu Zou; Minyue Dong
Journal:  Front Genet       Date:  2019-11-06       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.